Leadership Team

641

David R. Elmaleh, PhD

Scientific Founder and Chairman


Dr. Elmaleh is an Associate Professor at Harvard Medical School and the Director of Contrast Media Chemistry at the Massachusetts General Hospital. He is a renowned molecular imaging expert and inventor of numerous molecular imaging agents including three drugs that are in use in man or in late stage clinical trials, including the radiopharmaceutical preparation of (2FDG) which has been used in millions of PET imaging procedures. Dr. Elmaleh also recently received patent protection for the use of 18F-FDG PET for imaging atherosclerosis, for tracking inflammation within plaques, and for monitoring the response to drug therapy; a promising use that should be part of the future diagnostic armament. Dr. Elmaleh’s extensive research of the metabolic trapping of fatty acids and other imaging-designed drugs was a pivotal turning point in the development of molecular imaging. Influenced by the ingenious mathematical model developed by Dr. Louis Sokoloff for measuring brain glucose, Dr. Elmaleh, developed a parallel path for trapping fatty acid degradation via the beta-oxidation process, for which Professor Feodor Lynen received a Nobel Prize in 1964. Beta-methyl modified fatty acid, (BMIPP) is a commercially successful cardiac SPECT agent in Japan and Europe. He has also played a role in the development of Altropane, a Parkinson’s disease diagnostic agent (nominated as one of the 25 most valuable inventions of the brain decade by associated universities) that has completed Phase III clinical trials, several novel agents for early detection of dopamine and serotonin targeting drugs, and reversible acetyl choline esterase inhibitors. He also developed a new approach for molecular imaging with oligonucleotides and siRNA by facilitating the delivery to transformed cells using small molecular structures.

Dr. Elmaleh is a founder of several biotech companies including Molecular Insight (formerly Biostream) and Mersana (formerly NanoPharma) that recently closed a drug deals for over $700 million with big pharma. He also co-founded Puretech health that recently went public on The London Stock Exchange, at a valuation over $500 million.

Dr. Elmaleh holds a BS in Physics and Chemistry, and an MS and PhD in Organic Chemistry. Dr. Elmaleh is a recipient of numerous NIH and DOE grants. His recent work includes extensive research on imaging compounds, platforms to improve the speed and effectiveness of cardiovascular disease diagnosis, ischemia, infarction, and plaque formation which have enabled several drug technologies licensed from MGH to a new start-up. He is a co-author on over 130 publications and book chapters, an inventor of over 50 issued and pending patents in a range of disciplines, including molecular imaging and pharmaceuticals.

See more at:
http://en.m.wikipedia.org/wiki/David_R._Elmaleh
http://connects.catalyst.harvard.edu
http://www.genengnews.com/insight-and-intelligenceand153/top-13-serial-entrepreneurs/77899721/

1055

Karen Reeves, MD

President and Chief Medical Officer

Dr. Reeves joined AZTherapies in September 2017 with over twenty years of experience in Phase 1 through 4 drug development across multiple therapeutic areas, including neuroscience, oncology, immunology, and women’s health. Most recently Dr. Reeves held the position of Vice President, Head Global Clinical Submissions Quality and Innovation, Worldwide Research and Development, Pfizer, Inc. At Pfizer, Dr. Reeves held multiple leadership positions in Worldwide Research and Development and Worldwide Regulatory and Safety, including Vice President, Neuroscience Clinical Development. Dr. Reeves has proven leadership in numerous successful global development programs and approvals, including three marketed drugs in neuroscience. Under her direct leadership, Chantix gained FDA Priority Review and won the Prix Galien Award for Best Pharmaceutical, considered to be the highest accolade in Pharmaceutical Research & Development and has been approved in more than 8o countries. Prior to her most recent position at Pfizer, Dr. Reeves was Vice President, Head Global Medical Science, at Astellas Pharma Global Development Inc. Dr. Reeves has extensive experience in neurology and psychiatry both as a clinician drug developer and in business development and has publications in peer-reviewed journals. Dr. Reeves earned her B.A. from Yale University and her M.D. from University of Vermont Medical School and has held faculty positions at Harvard Medical School and Tufts Medical School.

644

Robert S. Warren

Chief Operating Officer and Chief Financial Officer


Mr. Warren joined AZTherapies in February 2015. Previously he was a corporate partner in the Life Sciences Practice Group at Foley Hoag LLP, headquartered in Boston. Mr. Warren has been lead counsel on dozens of biotech and M&A transactions, representing both strategic and private equity buyers and biotech company sellers, including the sale of iQuum to Roche for in 2014 and the sale of deCode Genetics to Amgen in 2013. Mr. Warren has extensive experience counseling public and private companies on complex corporate transactions, including mergers and acquisitions, financing transactions (including public offerings, PIPEs and venture capital investments) and strategic relationships. He is also a CPA. Mr. Warren earned his Juris Doctor from Northeastern University School of Law and his Bachelor of Science in Accountancy from University of Illinois.

911

David Brazier

Sr. Director, Clinical Operations

Mr. Brazier has over twenty-two years of clinical research experience managing and monitoring Phase I-III clinical trials. He previously served in various clinical trial roles with leading biopharma institutions, including Genetics Institute, Alkermes, Cubist, Enanta, and Dyax and has had significant clinical roles with two FDA approved therapies (Cubicin® and Kalbitor®). Mr. Brazier has worked on various therapeutic areas of research, including infectious disease, cardiology, neurology, adult and pediatric oncology, women’s health care, hematology, and medical imaging. Mr. Brazier received his Project Management Professional (PMP) certification through the globally recognized Project Management Institute (PMI) and  his Bachelor of Science Degree in Biology from Salem State University. Mr. Brazier also served eight years in the United States Air Force.

1000

Keith D. Greenfield

Director and EVP of Business Development


Mr. Greenfield is a serial entrepreneur who has been involved in launching and advancing several biotech companies. Mr. Greenfield is the President of The Dover Group, a financial services provider. In addition to being a founder of Seroton Inc. and joining the Board of Directors of AZTherapies, Mr. Greenfield is assisting the Company with its business development related initiatives. Previously, Mr. Greenfield worked with Dr. Elmaleh as a founder of Imaging Biopharmaceutical and Zebra Pharmaceutical which later merged into Biostream prior to going public as Molecular Insight at a $340 million pre-money valuation. Mr. Greenfield has been a co-founder and director of a number of biotechnology and healthcare related companies. Most recently, Mr. Greenfield was a co-founder, director and EVP of Corporate Development at IQuum, Inc., a medical diagnostic company that was sold to Roche in 2014 for over $400 million.

908

Juan B. Gonzales

Vice President of Quality and Technical Operations


Mr. Gonzalez has over 30 years of experience in Engineering and Quality Management, serving as Director of Validation, Technical Services and Head of Quality for CMO’s and drug sponsors, including Lonza Biologics, Dow Chemical, Avecia, Wolfe Laboratories, Artisan Pharma, BMS, OPK Biotech, and Shire. Mr. Gonzalez has extensive experience with biologics, DNA/RNA and small molecule manufacturing, pre-clinical and clinical studies, as well as commercial applications for both human and veterinary use. He has hosted numerous foreign and FDA regulatory inspections. In addition, Mr. Gonzalez has extensive experience with design, construction, retrofit, and qualification of biologic and small molecule facilities, processes, and laboratories, and has developed many quality programs supporting ISO, GMP, GLP, and GCP applications. Mr. Gonzalez holds a Bacehelor of Science in Engineering as well as Quality Management. Mr. Gonzalez has also served six years in the United States Air Force.